Introduction
Stratification for subsequent coronary events among patients with coronary artery disease (CAD) is of considerable interest because of the potential to guide secondary preventive therapies. Recently, we identified eight microRNAs (miRNAs), which facilitated acute coronary syndrome (ACS) diagnosis. In this study, we aimed to evaluate their potential role as prognostic biomarkers for cardiovascular disease.
Methods
The serum concentrations of eight candidate miRNAs -miR-19a, miR-19b, miR-132, miR-140-3p, miR-142-5p, miR-150, miR-186, and miR-210 were measured in a cohort of 1112 patients with documented CAD-including 430 patients with ACS and 682 patients with stable angina pectoris. Cardiovascular death was the main outcome measure.
Results
During a median follow-up of 4.0 years, most miRNAs reliably predicted cardiovascular death in ACS patients. Cox regression analyses indicated that in particular miR-132 (HR 2.85 per 1 SD increase, P ¼ 0.022), miR-140-3p (HR 2.88 per 1 SD increase, P ¼ 0.022), and miR-210 (HR 3.10 per 1 SD increase, P ¼ 0.039) were able to precisely predict cardiovascular death. Circulating miR-132, miR-140-3p, and miR-210 clearly improved various model performance measures, including C-statistics (AUC [area under the receiver-operating characteristic curve] for miR-132: 0.737; AUC for miR-140-3p: 0.756; AUC for miR-210: 0.754).
Conclusions
This is the largest study so far evaluating the prognostic value of circulating miRNAs in cardiovascular disease. Our study shows that single miRNAs derived from peripheral blood predict mortality in secondary prevention settings, and thereby represent valuable biomarkers for risk estimation in CAD.
Introduction
Stratification for subsequent coronary events among patients with coronary artery disease (CAD) is of considerable interest because of the potential to guide secondary preventive therapies. 1 -4 MicroRNAs (miRNAs) are a class of endogenous small noncoding RNAs found to be involved in cardiovascular pathophysiology. They are expressed in a tissue-specific manner, including heart tissue, where differential expression patterns have been identified with disease pathology. Circulating miRNAs are also found in various body fluids, including plasma and serum, and are protected from degradation in the circulation through association with lipids, proteins, or microparticles, making them attractive disease biomarker candidates. 5 In a previous study, using a three-phase approach of miRNA profiling and replication in patients with unstable angina pectoris and controls groups, and a final validation of a multi-miRNAs panel, we identified eight miRNAs, which facilitated acute coronary syndrome (ACS) diagnosis by identifying unstable angina pectoris. 6 It seems plausible that miRNAs, which are diagnostic for unstable angina, but not regarding ACS, may also be valuable prognostic markers of CAD, presumably via the detection of subclinical ischaemia. Therefore, it was the aim of this study to assess the association of circulating miRNAs levels with subsequent adverse cardiovascular events in a secondary prevention cohort of 1112 patients with documented CHD.
Methods

Study population
A total of 3800 patients, who underwent coronary angiography at the Department of Medicine II of the Johannes Gutenberg-University Mainz or the Bundeswehr-Zentralkrankenhaus Koblenz, were recruited in the AtheroGene Study between June 1999 and March 2000. 7, 8 The exclusion criteria were evidence of haemodynamically significant valvular heart disease, surgery or trauma within the previous month, known cardiomyopathy, known cancer, febrile conditions, or use of oral anticoagulant therapy within the previous 4 weeks. Subjects with missing information on the clinical presentation of CAD, missing laboratory measurements, or missing information on the cause of death were excluded (resulting in a subgroup of 3423 participants). In the next step, subjects with missing samples/low sample volume were additionally excluded, resulting in 1112 subjects in whom the present analyses were performed. As shown in Supplementary material online, Table S1 , there are no relevant differences in baseline characteristics between the subcohort and the overall cohort. All subjects gave written informed consent. The study was performed in accordance with the Declaration of Helsinki and approved by the Ethics Board of the Johannes Gutenberg-University Mainz and of the Physicians' chamber of the State Rhineland-Palatinate (Germany).
Data collection
At baseline, all participants were subjected to a standardized questionnaire containing sociodemographic information and medical history. In addition, information was taken from the patients' hospital charts. Coronary artery disease was diagnosed if the coronary angiogram showed at least one stenosis .30% in a major coronary artery. Unstable angina was diagnosed according to Braunwald. Acute myocardial infarction (MI) was either ST-segment elevation MI (STEMI) with significant elevation in at least two contiguous leads or non-ST-elevation MI (NSTEMI) based on clinic and positive in-house troponin concentrations. The final diagnosis of ACS (UA, NSTEMI, or STEMI) was made retrospectively based on the judgment of two physicians, with access to the history and nature of the presenting symptoms, medical history, results of physical examination, and all of the medical records available from index hospitalization (including the results of standard troponin testing).
Mean follow-up after discharge was four years. Information was obtained from the patients using a mailed standardized questionnaire. Information regarding adverse cardiovascular disease (CVD) events and treatment since discharge from the in-hospital rehabilitation clinic was obtained from the primary care physicians also by means of a standardized questionnaire. If a subject had died during follow-up, the death certificate was obtained from the local Public Health Department and the main cause of death was coded according to the International Classification of Diseases (ICD-9 pos. 390-459: ICD-10 pos. I0-I99 and R57.0). Adverse CVD events were defined either as CVD as the main cause of death (as stated in the death certificate), non-fatal MI, or non-fatal stroke. All non-fatal adverse events were reported by the primary care physicians.
Laboratory methods
At baseline, blood was drawn before angiography in a fasting state under standardized conditions and stored at 2808C until analysis. Within the recruiting sites, the sample was drawn before angiography and application of heparin. The miRNA measurements were performed from unthawed aliquots.
The serum concentrations of eight candidate miRNAs -miR-19a, miR-19b, miR-132, miR-140-3p, miR-142-5p, miR-150, miR-186, and miR-210 were measured by RT-qPCR, after isolation of circulating RNA from serum as described in Ref. 6 . Briefly, 3 volumes of TRIzol (Invitrogen) were mixed with 1 volume of serum and incubated at room temperature. Chloroform was added, and the mixture was shaken. After incubation at room temperature, the mixture was centrifuged at 14 000 × g and 48C for 15 min. The upper aqueous phase was transferred to a fresh reagent tube and 1.5 volumes of ethanol were added. Purification of RNA was performed with the miRNeasy kit (Qiagen) according to the manufactures' recommendations. RNA was eluted in 30 mL RNAse-free H 2 O. For normalization, serum samples were supplemented with 10 nM Caenorhabditis elegans miR-39 (cel-miR-39) after addition of TRIzol. 9, 10 C-reactive protein, troponin I, total cholesterol, HDL cholesterol, LDL cholesterol, and triglycerides measurements were done by routine methods in both participating hospitals. All biomarkers were measured in a blinded fashion.
Statistical methods
The study population was described with respect to various sociodemographic and medical characteristics. Spearman correlation coefficients were calculated to describe the relationship between miRNAs.
Cycle threshold (C t )-values were normalized to cel-miR-39 by the formula DC T ¼ C t [miRNA] 2 C t [cel-miRNA-39] for C t , 40 and DC T ¼ 40 in the case C t ≥ 40 (considered as undetermined). Difference in miRNA levels groups was tested by the Mann-Whitney test. The relation of miRNA concentrations with cardiovascular mortality during follow-up was assessed by Cox proportional hazards analyses adjusted for age (years) and gender. In additional models, the age-and sexadjustment was extended on conventional risk factors (hypertension, smoking status, diabetes, hyperlipidaemia, history of MI-Model 2), the emerging risk factors troponin T (Model 3), and Nt-proBNP (Model 4), left ventricular ejection fraction (LVEF) and number of diseased vessels (Model 5), and type of ACS diagnosis (Model 6). The assumptions for using Cox regression were tested, and no evidence of violation was found. Negative DC T values instead of the positive values were used as independent variables. This will reverse the inverse relationship between CT values and miRNA concentration which will enhance the interpretation of the hazard ratios. The hazard ratios P-values were corrected for multiple testing (number of miRNAs) using the method of Benjamini and Hochberg. 11 For all regression models, the C-index of Uno and colleagues was computed at follow-up time 350 weeks. Continued using a perturbation-resampling method described in Ref. 12, using 500 iterations. Finally, as a measure of effect strength and direction, the area under the receiver-operating characteristic curve was computed. 13 All statistical procedures were carried out using R 3.1.2 (http://www.r-project. org/). A P-value of ,0.05 was considered as statistically significant.
Results Table 1 shows the main sociodemographic and laboratory characteristics at baseline as a function of the diagnosis stable angina pectoris (SAP) or ACS in 1112 patients with clinically manifest CHD. The mean age of SAP patients was 64 years, while mean age was 63 in ACS patients. Participants were predominantly men, 79.9% in the SAP cohort, and 81.2% in the ACS cohort. Since more patients in the SAP group were on lipid-lowering medication, LDL cholesterol levels were lower in the SAP group, 117 and 127 mg/dL in median. Mean HDL cholesterol levels were fairly high with 49 mg/dL in the SAP, and 46 mg/dL in the ACS cohort. As expected, troponin and Nt-proBNP levels were clearly higher in the ACS cohort. During a median follow-up of 4.0 years, 78 patients (7.0%) experienced cardiovascular death or non-fatal MI: 43 patients within the ACS cohort, and 35 patients within the stable CHD cohort. Distribution of normalized miRNA levels according to the follow-up events, stratified for the items-no event during follow-up and cardiovascular event during follow-up is provided in Supplementary material online, Table S2 . Baseline levels of all eight miRNAs were higher in subjects with an event compared with event-free subjects. Table 2 shows normalized miRNA levels stratified for ACS and SAP. Here, levels of miRNAs were slightly higher in ACS, which may be attributable to the acute phase (blood for miRNA determination was drawn immediately before coronary angiography).
In order to assess the correlation of miRNA with each other Spearman rank correlation coefficients (R) were calculated for the eight miRNAs after normalization ( Table 3) In order to assess whether circulating miRNAs associate with cardiovascular mortality, analyses adjusted to age, gender and in additional models to classical cardiovascular risk factors and biomarkers with this endpoint were performed in the ACS and the overall cohort. During a median follow-up of 4.0 years, all measured miRNAs, with the exception of miR-142-5p, reliably predicted cardiovascular death in the ACS cohort ( Table 4 and Supplementary material online, Figure S1 ), even in the advanced adjustment models, comprising LVEF, number of diseased vessels, and type of ACS diagnosis. Cox regression analyses adjusted for age and gender showed that in particular mir-132 (HR 2.85 per 1 SD increase, P ¼ 0.022), miR-140-3p (HR 2.88 per 1 SD increase, P ¼ 0.022), and miR-210 (HR 3.10 per 1 SD increase, P ¼ 0.039) were able to precisely predict cardiovascular death. The C-statistics also showed excellent values for prediction of cardiovascular death. In particular, circulating miR-132, miR-140-3p, and miR-210 clearly improved c-statistics (AUC for miR-132: 0.737; AUC for miR-140-3p: 0.756; AUC for miR-210: 0.754; Supplementary material online, Figure S2 ).
In accordance, Table 5 shows the association of circulating miRNAs per 1 SD increase adjusted for age and gender with the endpoint cardiovascular death in the overall cohort. Five of eight circulating miRNAs reliably predicted cardiovascular death. Again, the predictive value of the miRNAs remained mainly unchanged, irrespective of adjustment for conventional risk factors, troponin, NT-proBNP, LVEF, and numbers of affected vessels. Cox regression analyses showed that in particular mir-19b (HR 2.19 per 1 SD increase, P ¼ 0.030), and miR-140-3p (HR 2.02 per 1 SD increase, P ¼ 0.030) were able to precisely predict cardiovascular death. The c-statistics also showed excellent values for prediction of cardiovascular death.
Discussion
In this study, we evaluated the predictive role of circulating miRNAs for cardiovascular mortality. To our knowledge, this is the first study that evaluates circulating miRNAs in a routine cohort of documented CAD patients. Based on a rigorous miRNA-screening procedure comprising an assay with 667 miRNAs and identification of 8 candidate miRNAs, 6 this prospective study identified an independent association between circulating levels of seven of these candidate miRNAs and the risk of cardiovascular death when used as single variables. Surprisingly, the observed risk of adverse cardiovascular events was much higher than expected, but similar for the seven positive miRNAs: Cardiovascular mortality rate per 1 SD increase of miR-19a, miR-150, and miR-186 was doubled, while event rate per 1 SD increase of miR-19b, miR-132, miR-140-3p, and miR-210 was even three times higher. In general, the predictive power was larger in ACS patients than in the overall cohort, and in subjects with CAD, which may be related to higher event rates in ACS patients. When subjects with stable CAD were analysed isolated, few miRNAs reached only borderline significance (Supplementary material online, Table S3 ). Less surprisingly, simultaneous assessment of miRNAs failed to provide additional prognostic information (data not shown), which is most likely because of the high correlation among each other. Nevertheless, the high correlation among the miRNAs (reflected by a high Spearman's rho in Table 3 ) may not be surprising since colinearity is one of the main issues in drawing predictive statistical models based on miRNA levels.
Pathophysiological implications
There are two main issues that need to be considered in relation to the CVD pathophysiology. First, as previously reported, the candidate miRNAs are potential markers for diagnosis of unstable angina. 6 In contrast to several other miRNAs, e.g. miR-499, which were reported to be deregulated in MI, 14 miRNAs of unstable angina reflect much more subtle levels of subclinical CVD. They seem much more sensitive in terms of underlying ischaemia, and may therefore be ideal markers of cardiovascular events in the mid-term. Second, accumulated experimental data clearly show that hypoxic conditions, mainly caused by underlying ischaemic disease, directly stimulate the miRNome. 15 Several recent studies have established a link between hypoxia and specific miRNAs. 16 Of the miRNAs that are regulated by hypoxia through the HIF-1 pathway, the most responsive and influential one is miR-210, which was identified as hypoxia inducible in all the cell types tested. 17 Under hypoxic conditions, HIF-1a drives overexpression of miR-210 and the resultant alteration of cellular processes, including cell cycle regulation, mitochondria function, apoptosis, and angiogenesis. 18 Likewise, a crucial cardiac role has also been implicated for miR-186 in response to hypoxia. 19 Since Spearman analysis shows potent correlation between the seven candidate miRNAs in our study, it seems plausible that the other miRNAs are also involved in hypoxia pathways. However, it needs to be considered that circulating miRNAs have been studied which may follow a different biology than intracellular miRNAs.
MicroRNAs in large-scale studies
Our study is the first one that evaluates circulating miRNAs in a routine secondary prevention cohort. To date, only one other large-scale study evaluated the predictive value of miRNAs-in a primary prevention cohort: In 820 apparently healthy subjects, three circulating miRNAs around endothelium-enriched miR-126 were associated with MI in the general population. 20 This study measured 19 miRNAs; however, data on the association with CV mortality were not available. The identified three miRNAs miR-223, miR-197, and miR-126 reached statistical significance after a broad adjustment to multiple measures like fibrinogen and waist-to-hip ratio. In a subanalysis, none of the three miRNAs was predictive for both early and late events.
Study limitations
Our study has some limitations that need to be addressed. Like all typical CHD populations, women are clearly underrepresented. Although we had a large sample of ACS patients, fatal CVD events were limited in this study population. Furthermore, our study population represents patients with stable CAD that underwent coronary angiography. This population might differ from stable CAD patients without the need for coronary intervention. Therefore, the predictive value of circulating miRNAs should also be assessed in those patients. From a laboratory view, C. elegans miR-39 had been used for normalization of miRNA data in our study. Using other 'housekeeping' miRNAs or normalization approaches might result in differently normalized data and thus might have an influence on the results. In addition, the use of two normalization methods, including an exogenous and an endogenous control might have further ensured the robustness of data. Finally, Cox regression analyses should be interpreted with caution, due to a possible over-adjustment.
Conclusion
This is the largest study so far evaluating the prognostic value of circulating miRNAs in cardiovascular disease. Based on a previous profiling-replication-validation application, for the very first time, our study shows that single miRNAs derived from peripheral blood-namely especially miR-132, miR-140-3p, and miR-210, predict mortality, and thereby could be valuable biomarkers for risk estimation in CAD.
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